Search results
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine...
Morningstar· 1 week agoThe trial evaluated the immunogenicity, tolerability and safety of V116 compared to PPSV23 (pneumococcal vaccine, polyvalent [23-valent]) in adults 50 years of age
On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23
FierceBiotech· 1 week agoFive months ago, Merck revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar ...
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 7 days agoAdditionally, UTHR's commitment to addressing the unmet medical needs of patients with chronic and...
...Expected to Reach USD 13.64 Billion by 2030 Predicts SNS Insider | Leading Companies – Abbott,...
Digital Journal· 2 weeks agoThe global Type 1 Diabetes Market, which was valued at USD 7.59 billion in 2022, is anticipated to...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 7 days agoNew York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli
SynOx takes rare tumour treatment to phase 3 with $75m Series B
BioPharma-Reporter· 1 week agoThe Series B round was led by the new investor Bioqube Ventures along with existing investors...
This biotech startup got the biggest venture capital deal in San Diego so far this year
U-T San Diego· 2 weeks agoSan Diego County recorded 55 venture capital deals totaling $1.57 billion in the first quarter...